Development of a scaleable, sustainable manufacutring process for a novel, high-value polypeptide

Leukolectin is a novel, patented molecule, exhibiting (in pre-clinical tests) remarkable benefits for the treatment of a range of skin, autoimmune and gastrointestinal disorders. Leukolectin is absent in many disease states, suggesting that its presence is critical for preventing the listed ailments. By creating a range of topical and oral medicaments containing Leukolectin, Seagarden, a Norwegian company who manufacture seafood ingredients and marine bioactives, hope to dramatically improve the severity of symptoms experienced by millions of suffers around the World. The project will be facilitated by Biocatalysts Ltd, a UK enzyme developer and manufacturer, who have vast experience of large-scale manufacturing of proteins such as leukolectin. Production of leukolectin via fermentation will ensure that production costs of these medical nutrition products are kept to a minimum, and that leukolectin is produced using a sustainable and environmentally-friendly process.